BioCryst Pharmaceuticals | BCRX - Assets


BioCryst Pharmaceuticals reported $446.42M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
BioCryst Pharmaceuticals USD 446.42M 10.76M Sep/2025
Chugai Pharma JPY 2.47T 285.01B Dec/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novavax USD 1.18B 156.66M Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025